文献速递关节外科创伤骨科

接受全关节置换术的退伍军人人群丙型肝炎病毒感染患病率:更新报告

Prevalence of Hepatitis C Virus Infection in the Veteran Population Undergoing Total Joint Arthroplasty: An Update.
PubMed 文献 · J Arthroplasty · 2020-08-18

该回顾性研究分析了2019年单中心285例接受初次全关节置换术的退伍军人患者,抗-HCV抗体阳性率为11.6%,丙型肝炎病毒血症患病率仅0.4%。与2007至2009年同一中心既往队列相比,病毒血症患病率从4.5%显著降至0.4%,抗体阳性率无统计学显著差异。

要点

  • 2019年285例术前筛查患者中33例(11.6%)抗-HCV抗体阳性。
  • 33例抗体阳性者中仅1例筛查时存在病毒血症,总体病毒血症患病率0.4%。
  • 与既往队列相比病毒血症患病率从4.5%降至0.4%,抗体阳性率无显著差异。

核心结论

  • 由于直接抗病毒药物可供使用,接受全关节置换术的退伍军人患者丙型肝炎病毒血症患病率从4.5%降至0.4%。
  • 仍建议外科医生尽量减少锐器损伤风险。

研究设计与样本

  • 回顾性综述,纳入2019年单家退伍军人医疗中心所有接受初次全关节置换术的患者,共285例术前筛查患者。
  • 与同一中心2007至2009年既往报告的接受全关节置换术患者队列数据进行比较。

主要发现

  • 285例术前筛查患者中33例(11.6%)抗-HCV抗体阳性。
  • 33例抗-HCV抗体阳性患者中仅1例在筛查时存在病毒血症,总体病毒血症患病率为0.4%。
  • 与既往队列相比,出生年份及抗-HCV抗体阳性率无统计学显著差异,但HCV病毒血症患病率显著下降。

关键数值与推荐

  • 2019年队列:抗-HCV抗体阳性率11.6%(33/285),病毒血症患病率0.4%(1/285)。
  • 既往2007至2009年队列:抗-HCV抗体阳性率8.4%,病毒血症患病率4.5%。

临床怎么用

  • 外科医生仍被建议尽量减少锐器损伤风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2012, we reported on the prevalence of hepatitis C virus (HCV) infection in Veterans Affairs (VA) patients undergoing total joint arthroplasty (TJA) at our center. In this patient population, 8.4% were antibody positive and 4.5% were viremic with HCV. In 2014, the first all-oral direct-acting antiviral treatment for hepatitis C became available. The Department of Veterans Affairs then underwent an aggressive program to eradicate hepatitis C from the veteran population. The purpose of this report is to provide updated information on the prevalence of HCV viremia among patients undergoing primary TJA at the same center. METHODS: A retrospective review was performed of all patients undergoing primary TJA at a single VA medical center in 2019. Anti-HCV antibody and HCV viremia prevalence were calculated. Comparisons were made to data from a previously reported cohort of patients who had undergone TJA at the same center from 2007 to 2009. RESULTS: Thirty-three (11.6%) of 285 patients screened preoperatively were positive for the hepatitis C antibody. Only one of the 33 anti-HCV-positive patients was viremic at the time of screening for an overall viremic prevalence of 0.4%. We found no statistically significant difference in the birth year, or anti-HCV antibody-positive rate from the prior cohort, but the prevalence of HCV viremia decreased significantly. CONCLUSION: Because direct-acting antiviral HCV treatment has become available, HCV viremia among VA patients undergoing TJA has been reduced from 4.5% to 0.4%. Surgeons are still advised to minimize the risk of sharps injury.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Shapiro CBH, Cheung RC, Giori NJ, et al. Prevalence of Hepatitis C Virus Infection in the Veteran Population Undergoing Total Joint Arthroplasty: An Update. J Arthroplasty. 2020. PMID: 32900563. doi:10.1016/j.arth.2020.08.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。